Chemclin Diagnostics Co., Ltd.

Equities

688468

CNE100005311

Medical Equipment, Supplies & Distribution

End-of-day quote Shanghai S.E. Other stock markets 03:30:00 16/05/2024 am IST			5-day change	1st Jan Change
7.57 ^CNY	+0.53%		-4.78%	-29.84%

03/05	Chemclin Diagnostics Launches Homegrown Immunodetection Kits	MT
29/04	Chemclin Diagnostics Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Tranche Update on Chemclin Diagnostics Co., Ltd.'s Equity Buyback Plan announced on November 30, 2023.

April 02, 2024

From January 1, 2024 to March 31, 2024, the company has repurchased 5,574,913 shares, representing 1.39% for CNY 44.65 million. With this, the company has completed the repurchase of 5,574,913 shares, representing 1.39% for CNY 44.65 million under the buyback announced on November 30, 2023.

Latest news about Chemclin Diagnostics Co., Ltd.

Chemclin Diagnostics Launches Homegrown Immunodetection Kits	03/05	MT
Chemclin Diagnostics Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	29/04	CI
Tranche Update on Chemclin Diagnostics Co., Ltd.'s Equity Buyback Plan announced on November 30, 2023.	02/04	CI
Chemclin Diagnostics Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	28/02	CI
Tranche Update on Chemclin Diagnostics Co., Ltd.'s Equity Buyback Plan announced on November 30, 2023.	03/01	CI
Chemclin Diagnostics to Buy Back Up to 60 Million Yuan Shares	30/11	MT
Chemclin Diagnostics Co., Ltd. announces an Equity Buyback for CNY 60 million worth of its shares.	30/11	CI
Chemclin Diagnostics Co., Ltd. authorizes a Buyback Plan.	28/11	CI
Chemclin Diagnostics Registers Hepatitis Testing Kit	10/11	MT
Chemclin Diagnostics Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	30/23/30	CI
Chemclin Diagnostics Registers Antibody Testing Kit	01/23/01	MT
Chemclin Diagnostics Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	29/23/29	CI
Chemclin Diagnostics Gets Medical Device Registration Certificate for Herpes Simplex Virus Detection Kit	13/23/13	MT
Chemclin Diagnostics Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	27/23/27	CI
Chemclin Diagnostics Gets Patent for Two Products	09/23/09	MT
Chemclin Diagnostics Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	27/23/27	CI
Chemclin Diagnostics Gets Patent for Two Analysis Kits	06/23/06	MT
Chemclin Diagnostics Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	28/22/28	CI
Chemclin Diagnostics Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	29/22/29	CI
Chemclin Diagnostics Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	27/22/27	CI
Chemclin Diagnostics Co., Ltd.(SHSE:688468) added to Shanghai Stock Exchange Composite Index	12/22/12	CI
Chemclin Diagnostics Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	25/22/25	CI
Chemclin Diagnostics Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021	28/21/28	CI

Chart Chemclin Diagnostics Co., Ltd.

Duration

Period

More charts

Company Profile

Chemclin Diagnostics Co Ltd is a China-based company mainly engaged in the research and development of clinical immuno chemiluminescence diagnostic test reagents and instruments. The Company's products are LiCA series of diagnostic reagents based on light-induced chemiluminescence and Chemclin series of diagnostic reagents and instruments based on enzymatic chemiluminescence, which are mainly used in infectious diseases (such as hepatitis B, hepatitis C, Acquired Immunodeficiency Syndrome, syphilis, hepatitis A, hepatitis E) detection of markers, tumor markers, thyroid hormones, reproductive endocrine hormones, diabetes, myocardial markers and inflammation. The Company mainly operates its businesses in the domestic market.

Sector

Medical Equipment, Supplies & Distribution

Calendar

23/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Diagnostic & Testing Substances

	1st Jan change	Capi.
CHEMCLIN DIAGNOSTICS CO., LTD.	-29.84%	42Cr
BIOMÉRIEUX	-4.57%	1.23TCr
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-4.35%	810.32Cr
DIASORIN S.P.A.	+8.91%	586.66Cr
LANTHEUS HOLDINGS, INC.	+30.81%	551.73Cr
AUTOBIO DIAGNOSTICS CO., LTD.	-7.42%	429.48Cr
10X GENOMICS, INC.	-54.27%	315.91Cr
ANDON HEALTH CO., LTD.	+14.44%	271.93Cr
VITROLIFE AB	-2.21%	237.38Cr
MYRIAD GENETICS, INC.	+28.53%	223.19Cr

Diagnostic & Testing Substances